Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Sovesudil (PHP-201) in Primary Open-angle Glaucoma or Ocular Hypertension
NCT04863365Phase 3Unknown
- Sponsor
- pH Pharma Co., Ltd.
- Start
- Nov 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of AMA0076 in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by pH Pharma Co., Ltd.. Status: unknown.
02
Drugs
AMA0076
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT04863365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04863365.